Latest Period
Q2 2026
Security Snapshot
GT Biopharma, Inc. - Common Stock (GTBP) Institutional Ownership
CUSIP: 36254L308
13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026
Institutions Reporting
57
Shares (Excl. Options)
2,112,169
Price
$0.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- GTBP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,112,169
- Total 13F value
- $1,029,299
- Portfolio coverage rank
- 0%
- Share change
- +499,135
- Value change
- +$253,187
- Number of holders
- 57
- Shares outstanding
- 3,148,458
- SEC-reported price per share
- $0.31
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GTBP - GT Biopharma, Inc. - Common Stock is tracked under CUSIP 36254L308.
- 57 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 39 to 57 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $656,720 to $1,029,299.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 57 institutions filings for Q2 2026.
Security key
36254L308
Latest holder period
Q2 2026
13F holders
57
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
GTBP full holder history
GT Biopharma, Inc. SEC filings
GT Biopharma, Inc. company facts
GT Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36254L308:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GTBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Five Narrow Lane LP | 10% | $552,386 | 253,388 | Five Narrow Lane LP | 13 May 2025 | |||
| CYTOVANCE BIOLOGICS INC | 9.8% | $478,416 | 219,457 | CYTOVANCE BIOLOGICS INC | 30 Sep 2024 | |||
| BRISTOL INVESTMENT FUND LTD | 2.4% | $171,405 | 74,524 | Bristol Investment Fund, Ltd. | 29 May 2025 |
As of 30 Jun 2026, 57 institutional investors reported holding 2,112,169 shares of GT Biopharma, Inc. - Common Stock (GTBP). This represents 67% of the company’s total 3,148,458 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 12% | 376,399 | -17% | 0% | $184,436 |
| GEODE CAPITAL MANAGEMENT, LLC | 8.5% | 266,788 | -9.4% | 0% | $130,648 |
| VANGUARD FIDUCIARY TRUST CO | 7.2% | 225,938 | 0% | 0% | $110,710 |
| HRT FINANCIAL LP | 3.4% | 107,140 | 0% | $52,000 | |
| Everhart Financial Group, Inc. | 3.2% | 100,000 | 0% | $48,970 | |
| Arax Advisory Partners | 3% | 93,627 | 0% | 0% | $45,850 |
| Opal Wealth Advisors, LLC | 2.6% | 81,811 | 0.01% | $40,063 | |
| NORTHERN TRUST CORP | 2.4% | 75,461 | 0% | $36,953 | |
| ALONGSIDE, LLC | 2% | 64,000 | 0.01% | $31,341 | |
| 49 WEALTH MANAGEMENT, LLC | 2% | 64,000 | 0.01% | $31,341 | |
| Cetera Investment Advisers | 1.8% | 55,936 | 0% | $27,392 | |
| SeaCrest Wealth Management, LLC | 1.6% | 50,100 | +0.2% | 0% | $24,534 |
| KITCHING PARTNERS, LLC | 1.6% | 50,000 | 0.02% | $24,485 | |
| Integrated Wealth Concepts LLC | 1.3% | 40,012 | +100% | 0% | $19,594 |
| PNC Financial Services Group, Inc. | 1.3% | 40,000 | 0% | $19,600 | |
| OSAIC HOLDINGS, INC. | 1.2% | 38,500 | +83% | 0% | $18,857 |
| LPL Financial LLC | 1.2% | 36,379 | +20% | 0% | $17,815 |
| StoneX Group Inc. | 0.74% | 23,258 | +58% | 0% | $8,667 |
| MORGAN STANLEY | 0.72% | 22,573 | +36% | 0% | $11,054 |
| Keel Point, LLC | 0.66% | 20,768 | 0% | 0% | $10,170 |
| Private Wealth Management Group, LLC | 0.64% | 20,000 | 0% | 0% | $9,794 |
| SAGESPRING WEALTH PARTNERS, LLC | 0.64% | 20,000 | 0% | $9,794 | |
| Corient Private Wealth LP | 0.64% | 20,000 | 0% | $10,000 | |
| Coston, McIsaac & Partners | 0.54% | 17,092 | 0% | 0% | $8,000 |
| Caitlin John, LLC | 0.52% | 16,500 | 0% | 0% | $8,080 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,112,169 | $1,029,299 | +$253,187 | $0.49 | 57 |
| 2026 Q1 | 1,613,044 | $656,720 | +$139,088 | $0.41 | 39 |
| 2025 Q4 | 483,011 | $373,734 | +$113,728 | $0.79 | 38 |
| 2025 Q3 | 369,208 | $217,520 | +$21,414 | $0.59 | 20 |
| 2025 Q2 | 198,676 | $711,263 | +$381,370 | $3.58 | 21 |
| 2025 Q1 | 99,688 | $220,497 | -$29,000,935 | $2.15 | 20 |
| 2024 Q4 | 1,244,880 | $29,297,553 | +$4,192 | $3.05 | 18 |
| 2024 Q3 | 1,246,007 | $35,300,829 | +$5,339,749 | $2.31 | 15 |
| 2024 Q2 | 1,080,160 | $38,124,773 | +$37,905,403 | $2.83 | 16 |
| 2024 Q1 | 75,442 | $348,558 | +$348,261 | $4.43 | 15 |
| 2023 Q4 | 208 | $53 | +$53 | $0.26 | 2 |